Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796651 · ClinicalTrials.gov registry record · Phase 2
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02796651: Completed Phase 2 study, sponsored by AstraZeneca.
NCT02796651 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 132 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02796651, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
Primary Outcome
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist®
Interventions
- DRUG Formoterol furmarate (20 μg)
- DRUG Formoterol fumarate (6 μg)
- DRUG Placebo for formoterol fumarate
- DRUG Formoterol fumarate (12 μg)
- DRUG Formoterol fumarate (40 μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2016-12-07 |
| Phase | Phase 2 |
What the finished NCT02796651 record still lists
NCT02796651 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Formoterol furmarate (20 μg) is the first listed.
NCT02796651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02796651 about?
NCT02796651 is a clinical study titled "Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)". To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
What is the current status of trial NCT02796651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2016-06-30. Estimated completion is 2016-12-07.
What interventions are being tested in trial NCT02796651?
The interventions under investigation include: Formoterol furmarate (20 μg) (DRUG), Formoterol fumarate (6 μg) (DRUG), Placebo for formoterol fumarate (DRUG), Formoterol fumarate (12 μg) (DRUG), Formoterol fumarate (40 μg) (DRUG).
Who is sponsoring clinical trial NCT02796651?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02796651's enrollment target sits among peer trials
132 539th of 2000 higher than 1,460 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI